| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/amneal-pharmaceuticals-amrx-q1-earnings-and-revenues-surpass-estimates","as_of":"2026-04-22T13:12:40.941923+00:00","canonical_url":"https://www.nasdaq.com/articles/amneal-pharmaceuticals-amrx-q1-earnings-and-revenues-surpass-estimates","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/amneal-pharmaceuticals-amrx-q1-earnings-and-revenues-surpass-estimates","article_chars":3939,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_176a460ff31e70e2","canonical_host":"nasdaq.com","canonical_is_aggregator":false,"canonical_url":"https://www.nasdaq.com/articles/amneal-pharmaceuticals-amrx-q1-earnings-and-revenues-surpass-estimates","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-22T13:17:43.372829+00:00","extraction_method":"trafilatura","fetched_description":"Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for no","fetched_title":"Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates | Nasdaq","final_url":"https://www.nasdaq.com/articles/amneal-pharmaceuticals-amrx-q1-earnings-and-revenues-surpass-estimates","html_truncated":false,"paywall_likely":false,"publisher_domain":"nasdaq.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/amneal-pharmaceuticals-amrx-q1-earnings-and-revenues-surpass-estimates","source_event_id":"evt_0c0e8b1d8fc8","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"46f72b2181919b07","kind":"new_listings","published_at":"2026-04-22T11:20:01+00:00","publisher_domain":"nasdaq.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["March 2026","March 2024","May 9"],"entities":[{"asset_class":"equity","name":"Amneal Pharmaceuticals","relevance":"high","symbol":"AMRX","type":"company"},{"asset_class":"index","name":"S&P 500","relevance":"medium","symbol":"","type":"index"},{"asset_class":"benchmark","name":"Zacks Consensus Estimate","relevance":"high","symbol":"","type":"estimate_benchmark"},{"asset_class":"rating","name":"Zacks Rank","relevance":"medium","symbol":"","type":"rating_tool"}],"event_type":"earnings","information_gaps":["Exact reported revenue amount for the quarter ended March 2026 is not provided in the excerpt (only the +1.86% surprise is stated).","The article references management commentary on the earnings call, but no specific commentary details are included in the provided text.","The signal type guidance mentions discovery_new_listings_delta, but the provided article content is about earnings; no new listing information is present in the excerpt.","The excerpt includes additional unrelated content about Bitcoin; it is not connected to AMRX earnings within the provided text."],"key_facts":["Quarter ended March 2026: adjusted quarterly earnings were $0.14 per share.","$0.14 EPS beat the Zacks Consensus Estimate of $0.09 per share.","Year-ago adjusted earnings were $0.12 per share.","The article states an earnings surprise of 55.56%.","The article states revenues surpassed estimates by +1.86% (exact revenue figure not provided in the excerpt).","Over the last four quarters, the company surpassed consensus EPS estimates four times (per article).","Shares have added about 2.3% since the beginning of the year versus the S&P 500\u2019s gain of 6.2% (per article).","Ahead of the release, estimate revisions trend was described as mixed and the stock had a Zacks Rank #3 (Hold) (per article).","Current consensus EPS estimate for the coming quarter is $0.14 on $648.93 million in revenues (per article).","Current consensus EPS estimate for the current fiscal year is $0.57 on $2.6 billion in revenues (per article).","Zacks Industry Rank for Medical - Drugs is currently in the bottom 44% of 250+ Zacks industries (per article)."],"numeric_claims":[{"label":"Q1 adjusted EPS","value":"$0.14"},{"label":"Zacks Consensus EPS","value":"$0.09"},{"label":"Earnings surprise (stated)","value":"55.56%"},{"label":"Year-ago EPS","value":"$0.12"},{"label":"Revenue surprise (stated)","value":"+1.86%"},{"label":"YTD AMRX performance (stated)","value":"+2.3%"},{"label":"YTD S&P 500 performance (stated)","value":"+6.2%"},{"label":"Zacks Rank","value":"#3 (Hold)"},{"label":"Coming quarter consensus EPS","value":"$0.14"},{"label":"Coming quarter consensus revenues","value":"$648.93 million"},{"label":"Current fiscal year consensus EPS","value":"$0.57"},{"label":"Current fiscal year consensus revenues","value":"$2.6 billion"}],"primary_claim":"Amneal Pharmaceuticals (AMRX) beat the Zacks Consensus Estimate for Q1 adjusted EPS ($0.14 vs. $0.09) and surpassed revenue estimates by +1.86% for the quarter ended March 2026.","relevance_score":0.72,"sentiment":"mixed","source_quality":"high","summary":"Amneal Pharmaceuticals (AMRX) reported Q1 adjusted EPS of $0.14, beating the Zacks Consensus Estimate of $0.09, and reported revenues that were described as surpassing estimates by +1.86% for the quarter ended March 2026. The article also states the stock has a Zacks Rank #3 (Hold) based on mixed estimate revisions ahead of the release.","topics":["earnings surprise","adjusted EPS","revenue surprise","earnings outlook","estimate revisions","Zacks Rank","pharmaceutical industry"]},"source":"Nasdaq Stocks","source_domain":"nasdaq.com","summary":"Amneal (AMRX) delivered earnings and revenue surprises of +63.64% and +1.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?","tickers":["AMRX"],"title":"Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates","url":"https://www.nasdaq.com/articles/amneal-pharmaceuticals-amrx-q1-earnings-and-revenues-surpass-estimates"}... |